Member Info for Globalcrossings

TIDMHSTN TIDMKEIF RNS Number : 4772I Hansteen Holdings plc 11 March 2010 ? GENERAL TEXT AMENDMENT The following amendment has been made to the 'Statement re. possible offer for Kenmore European Industrial Fund Limited ("KEIF")' announcement released on 11 March 2010 at 17.08 under RNS No 4713I The following numerical point has been inserted: 4. there is a material change of circumstances at KEIF, including, inter alia, the announcement of a significant equity fundraising by KEIF. All other details remain unchanged. The full amended text is shown below. Hansteen Holdings plc ("Hansteen" or "the Company") Statement re. possible offer for Kenmore European Industrial Fund Limited ("KEIF") On 25 November 2009 Hansteen announced that it had acquired a stake of approximately 12.0 per cent. in KEIF and had made an approach to the Board of KEIF in relation to a potential offer by Hansteen for the remaining issued and to be issued ordinary share capital of KEIF. In accordance with Rule 2.8 of The City Code on Takeovers and Mergers (the "Code") Hansteen announces that it is no longer considering making an offer for KEIF. Important Notice: For the purposes of Rule 2.8 of the Code, Hansteen reserves the right (on behalf of itself and anyone acting in concert with it) to announce an offer or possible offer for KEIF and/or to take any other action which would otherwise be restricted under Rule 2.8 of the Code within the six months from the date of this announcement in the event that: 1. the agreement or recommendation of the Board of KEIF is given to the making of such an offer or the taking of any such other action; 2. a third party announces an offer or a possible offer for KEIF; 3. KEIF announces a 'whitewash proposal' or a 'reverse takeover' (each as defined in the Code); or 4. there is a material change of circumstances at KEIF, including, inter alia, the announcement of a significant equity fundraising by KEIF. For further information please contact: +--------------------------------------------------------------------------------+ | Hansteen Holdings plc | | Ian Watson/Morgan Jones | | Tel: 020 7016 8820 | +--------------------------------------------------------------------------------+ | | +--------------------------------------------------------------------------------+ | | +--------------------------------------------------------------------------------+ | Tavistock Communications | | Jeremy Carey/Gemma Bradley | | Tel: 020 7920 3150 | +--------------------------------------------------------------------------------+ This information is provided by RNS The company news service from the London Stock Exchange END OFDKFLFFBXFBBBQ (END) Dow Jones Newswires March 12, 2010 02:00 ET (07:00 GMT)

RNS Number : 3544I Norseman Gold PLC 10 March 2010    THE FOLLOWING ANNOUNCEMENT REPLACES RNS 3504I RELEASED AT 8AM TODAY.  "OK DECLINE RESERVE TABLES AND STATEMENTS" NOW INCLUDED. ALL OTHER DETAILS REMAIN UNCHANGED.     Norseman Gold Plc ('Norseman Gold' or 'the Company') Operations Update March 2010   Norseman Gold, the AIM-listed and ASX-listed Australian gold production company, provides an update to its operations at the Norseman Gold Project.   Summary   ·     The focus on production operations has continued with improvements at the Harlequin Decline.  The Bullen Decline has continued to disappoint and will not recover its production profile in the current financial year.  The OK Decline continues to be on schedule but cannot be accelerated to make up for the Bullen production shortfall.  As a consequence the Company has revised its production guidance down to 65,000 ounces for the current 2009/10 financial year.  The production forecast for the financial year commencing 1st July 2010 remains unchanged at between 105,000 and 110,000 ounces.   ·     At the OK Decline, the first analysis of the Star of Erin orebody has been completed.  The initial Star of Erin reserve is 17,000 ounces which increases the OK Decline reserve by over 30%.  Drilling into the Star of Erin orebody continues with more than 10,000 metres of drilling yet to be completed, giving confidence that further resources will be delineated in this orebody.   ·     At North Royal, the Company's potential fourth mine, dewatering has continued with the pit now over one third dewatered.  First round drilling on the southern end of the pit has returned promising results particularly around a footwall structure.  Follow-up extensional and infill drilling will commence this month.  Work will also commence on regulatory approvals in anticipation of commencing mining by the last quarter of the 2010 calendar year.   ·     Surface drilling has commenced on Crown Reef, potentially the Company's fifth mine, with a structure intersected in the expected position in the initial drill holes.  Assay results are pending.   ·     The Company will continue to invest funds on capital and ore development and exploration programmes to drill and delineate further resources as part of its 'fill-the-mill' strategy.     Production   The Company currently has three operating mines, Bullen, Harlequin and the developing OK Decline.  It is also exploring and developing for potential fourth and fifth mines to fulfil its strategy of filling its treatment plant to capacity.   The focus on capital and ore development at the Harlequin Decline has had a positive impact on the production profile of the mine.  Capital development has

LONDON (Dow Jones)--Car retailer Inchcape PLC (INCH.LN) Wednesday posted a 26% rise in full-year pretax profit but said it is cautious for 2010 and doesn't expect a global recovery to start until "well into the second half" of this year, due to weak consumer confidence and rising unemployment in many of its markets. Inchcape said it isn't paying a dividend for 2009 due to challenging trading conditions, and said it hasn't yet decided if it will pay one in 2010. The retailer said it expects to benefit from market momentum in Hong Kong and Australia and stable industries in Belgium and Finland this year, but is also expecting market declines in the U.K., Greece, Singapore, Eastern Europe and Russia. For the year to Dec. 31, Inchcape posted pretax profit of GBP136.7 million, compared with GBP108.2 million in 2008. Sales fell to GBP5.6 billion from GBP6.3 billion. As a result of its GBP234.3 million rights issue last year, Inchcape had GBP800,000 of net cash at the end of 2009, compared with GBP407.8 million of net debt at the end of 2008. Company Web site: www.inchcape.com -By Rachael Gormley, Dow Jones Newswires; 44-20-7842-9308; rachael.gormley@dowjones.com (END) Dow Jones Newswires March 10, 2010 02:19 ET (07:19 GMT)

TORONTO, ONTARIO--(Marketwire - March 9, 2010) - Allied Gold Limited (TSX:ALG)(AIM:AGLD)(ASX:ALD) THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES AND SHALL NOT BE DISSEMINATED TO UNITED STATES NEWS SERVICES HIGHLIGHTS - New resource estimates for Pigiput and Pigibo deposits give total Measured and Indicated Resources of 48.1 million tonnes at 1.35 g/t gold, at 0.5g/t gold block cut-off, equivalent to 2.08 million ounces of gold - 170% increase in estimated contained gold in Measured and Indicated resources compared to previous estimates - Pigiput total Measured and Indicated resources estimated as 41.0 million tonnes at 1.38 g/t gold for 1.82 million ounces of gold - Pigibo total Measured and Indicated resources estimated as 7.1 million tonnes at 1.18 g/t gold for 0.27 million ounces of gold - Total group combined Measured and Indicated Resources of 107.9 million tonnes at 1.39 g/t gold for 4.83 million ounces of gold (Simberi, 78.4 million tonnes at 1.27 g/t for 3.20 million ounces of gold and Gold Ridge, 29.5 million tonnes at 1.72 g/t for 1.63 million ounces of gold). - Reserve estimation to be undertaken on completion of Phase III drilling at Pigibo, Pigiput and north-east towards SE Sorowar Allied Gold has received new resource estimates for Pigiput and Pigibo deposits from consultants, Golder and Associates, totalling 48.1Mt @ 1.38g/t Au in Measured and Indicated categories for 2.08 million ounces of gold, using a 0.5g/t Au block cut-off. Mineral Resources classified as Inferred are estimated to be 38.5Mt @ 1.00 g/t Au for 1.24 Moz of gold and 86.6Mt @ 3.70g/t Ag for 10.3 Moz of silver. Compared to the previous estimates, this represents a significant consolidation, with the equivalent of net 30.4 Mt @ 1.34 g/t Au (1.31 Moz gold) converted to Measured and Indicated, and net expansion of total resources, by 29.4Mt @ 1.04g/t Au (0.98 Moz gold). Phase III drilling is on-going with efforts focussed on testing down dip at Pigipbo and the open north eastern side of Pigiput. A further seventeen (17) diamond core holes for 4,360 metres, have been completed since the resource database close-off and two (2) are in progress. The holes are part of a phased in-fill and step-out program, commenced in May 2009, designed to support the A$10 million Sulphide and Oxide Expansion Studies based around the Pigiput Deposit. These studies target increasing total oxide and sulphide production to in excess of 200,000oz p.a. by 2012. A particular focus of the Phase III programme is to test the presently open north-eastern limit of Pigiput, with the aim of establishing a link with known mineralisation already immediately north at southeast Sorowar. The new estimates for Pigiput and Pigibo bring Allied Gold's total Measured and Indicated Resources at the flagship Simberi Gold Mine (PNG) and the Gold Ridge Project (Solomon Islands) to 4.81 million ounces being: Simberi(1) 78.4Mt @ 1.27 g/t Au for 3.20 Moz of gold Gold Ridge(2) 29.5Mt @ 1.72 g/t Au fo

LONDON (Dow Jones)--Biotechology company Ark Therapeutics Group PLC (AKT.LN) Tuesday said it has received offer approaches and has dropped its appeal against European regulators' decision not to approve its flagship brain cancer treatment for sale. Ark said it has received approaches which may or may not lead to an offer being made for the company. It didn't name any suitors or the terms these approaches were pitched at but said it has entered talks with a number of parties. There is no certainty a formal offer will be made, Ark said. Ark added Tuesday it withdrew its marketing application for Cerepro after the European Medicines Agency's oncology advisory board said Ark would need to conduct another clinical trial of the brain cancer treatment before it could be reconsidered for approval. The agency rejected Cerepro in January. The advisory board didn't consider that the Phase III trial Ark conducted provided sufficiently reliable evidence of clinical benefit, Ark said. Company Web site: www.arktherapeutics.com -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com (END) Dow Jones Newswires March 09, 2010 02:19 ET (07:19 GMT)

To buy a few if it drops any further.. GLA

By Anita Likus Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Recruiter Michael Page International PLC (MPI.LN) Friday reported an 85% fall in full-year pretax profit but said it is well positioned to significantly improve its performance this year as markets stabilize. The company said that market conditions and headcount have stabilized with some geographies showing signs of improvement. It added that it is hiring in a number of locations, after reducing its headcount by 1,394 since the start of 2009 to 3,549. "Whilst the strength of this recovery is uncertain, we believe that, with a strong balance sheet position and spare capacity in the business, we are well positioned to improve significantly our performance in 2010," said Chief Executive Steve Ingham. He added that he is encouraged by the 10% sequential growth in gross profit in the fourth quarter of last year. Still, pretax profit for the year to Dec. 31 fell to GBP21.1 million from GBP140.1 million in the same period a year earlier while revenue fell 26% to GBP716.7 million. Recruiters have been hit hard as the credit crunch, and subsequent economic recession, caused companies to shrink to save money, resulting in job cuts and hiring freezes. Although there are signs of economic recovery, individuals are still cautious about changing jobs. The company generated GBP114.8 million of cash from operations and has net cash of GBP137.2 million. The company maintained its dividend at 8 pence per share. Michael Page shares closed Thursday at 393 pence, giving the company market capitalization of GBP1.25 billion. -By Anita Likus, Dow Jones Newswires; +44 20 7842 9407; anita.likus@dowjones.com (END) Dow Jones Newswires March 05, 2010 02:19 ET (07:19 GMT)

RNS Number : 1229I Proximagen Neuroscience Plc 05 March 2010      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.   For immediate release 5 March 2010   RECOMMENDED CASH OFFER FOR THE   ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL   OF MINSTER PHARMACEUTICALS PLC   BY PROXIMAGEN NEUROSCIENCE PLC   Compulsory Acquisition of Outstanding Minster Pharmaceuticals plc Shares   On 4 January 2010, the boards of Proximagen Neuroscience plc ("Proximagen") and Minster Pharmaceuticals plc ("Minster") announced the recommended offer by Proximagen for the entire issued and to be issued share capital of Minster (the "Offer"). On 17 February 2010 Proximagen announced that, as at 1.00 p.m. on 16 February 2010 (the "First Closing Date"), valid acceptances of the Offer had been received in respect of a total of 50,805,875 Minster Shares representing approximately 86.25 per cent. of the entire issued share capital of Minster and declared the Offer to be unconditional as to acceptances. As at 1.00p.m. on 4 March 2010, valid acceptance of the Offer had been received in respect of a total of 64,929,488 Minster Shares representing approximately 91.26 per cent of the entire issued share capital of Minster.   These acceptances include acceptances received in respect of 32,891,853* Minster Shares (representing approximately 55.84 per cent. of the existing issued share capital of Minster) which were subject to irrevocable commitments procured by Proximagen from all of the Minster Directors and certain other shareholders.   * The 32,891,853 Minster Shares subject to irrevocable commitments as set out above, differs by 200 Minster Shares from the number of Minster Shares subject to irrevocable commitments as set out in the Offer Document. The difference is due to an administrative error in the Offer Document.   Offer Remains Open for Acceptance   The Offer will remain open until further notice.   To accept the Offer:   ·          If you hold Minster Shares in certificated form (that is, not in CREST), the form of acceptance should be completed, signed, witnessed and returned together with your share certificate in accordance with the instructions contained in the Offer Document and the form of acceptance.   ·          If you hold Minster Shares in uncertificated form (that is, in CREST), you should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document.   Settlement   Settlement of the consideration to which Minster Shareholders are entitled under the Offer will be effected by the despatch of cheques or the crediting of CREST accounts:

Post 9/11 in 2003 the US Govt imposed a wide range of new "laws/efforts" called the "Patriot Act" to try and prevent terrorism which included making it harder for Americans to have oversees bank accounts, such as doing financial transactions i.e. trading accounts etc... and vice versa, for foreigners to have accounts in the USA. This was part of an effort to help curb money laundering, to make it harder for the Bin Landens of this world to fund their activities. To make it not a worth while venture for the average American to be be a "private investor" in the markets oversees, they tax the h£ll out of us with capital gains... With that said, it's a bit easier for the institutional buyers... Hope this helps....

The NY markets will have little if any effect on the share price... GLA

http://www.screencast.com/users/globalcrossings/folders/Jing/media/dcc7b479-491c-4c86-8a42-7c205a421376

Cheers mate for the info... Ooof, I'm hurting today...

So well today. A bit hung over...

Cheers... I was just wondering if the mm's were taking only "limit orders" to sell....

Are they easily sold or in order to sell are they manual trades..? Many Thanks....

RNS Number : 0811I Serabi Mining plc 04 March 2010   FOR IMMEDIATE RELEASE 4 March 2010   Serabi Mining PLC ("Serabi" or the "Company") Statement regarding share price movement   The Board of Serabi notes the recent activity in its shares and movements in the Company's share price and confirms that it is currently in preliminary discussions with a third party regarding a possible merger (the "Discussions"). The Discussions are very preliminary in nature and there can be no certainty that the potential merger will ultimately proceed nor any offer be forthcoming.   In relation to this announcement, shareholders are advised to take no action in relation to their shareholdings in the Company. A further announcement will be made in due course as appropriate.   Relevant Securities in Issue    The following information is provided in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code").   The Company confirms that it has in issue:   1.          327,740,595 ordinary shares of 0.5 pence each ("Ordinary Shares") as at the close of business on 3 March 2010 and the Ordinary Shares in the Company are admitted to trading on AIM under the UK ISIN code GB00B074J639.   2.          £300,000 Convertible Loan Agreement convertible at any time up to 31 October 2014 into up to a maximum further 21,001,228 new Ordinary Shares (assuming the maximum amount of accrued interest between drawdown and the repayment date of £15,018.42 is converted into new Ordinary Shares).   Enquiries:   Serabi Mining PLC Clive Line, Finance Director Tel: 0207 246 6830 Beaumont Cornish Limited Michael Cornish Tel: 0207 628 3396   Beaumont Cornish Limited ("Beaumont Cornish") which is authorised in the United Kingdom by The Financial Services Authority, is acting for Serabi in relation to any potential offer and is not advising any other person, and accordingly will not be responsible to anyone other than Serabi for providing the protections afforded to customers of Beaumont Cornish or for providing advice in relation to any potential offer.     Dealing Disclosure Requirements    Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any  person is, or becomes, "interested" (directly or indirectly) in 1% or more of  any class of "relevant securities" of the offeror or Serabi (the offeree company), all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following

RNS Number : 0352I Niche Group (The) PLC 04 March 2010   The Niche Group plc   ("Niche" or "the Company")     Restoration of Trading on AIM       Further to the announcement made by the Company on 29 January 2010, the Board of Niche is pleased to announce that the temporary suspension of the trading of its ordinary shares on AIM is to be lifted from 7.30am on 4 March 2010.   On 20 July 2009, the Company announced that it had issued 46,255,674 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") pursuant to an agreement with the shareholders of Ely Management Operations Limited ("EMO") to acquire a 5.5 per cent. stake in EMO.  The Company has today been notified that the shareholders of EMO have today disposed of the Ordinary Shares in full and that they no longer have a notifiable interest in the capital of the Company.    The Company has been notified that Old Church Street Holdings Limited is the new registered owner of the Ordinary Shares.  The beneficial owners of the Ordinary Shares are as follows:     Beneficial Owner Number of Ordinary Shares Percentage holding % Donan Boyle 15,001,840 8.64 Mark Pearson 15,001,840 8.64 Old Church Street Holdings Limited 16,251,994 9.36 46,255,674 26.64     Finally, the Board is pleased to announce that the Company has today entered into an agreement with the shareholders of EMO to dispose of the Company's 5.5 per cent. holding in EMO in exchange for £185,000 in cash.   The proceeds will be used to satisfy the fees associated with the aborted acquisition of EMO as well as to provide general working capital for the Company over the next 12 months.           Enquiries:   The Niche Group plc                       Christopher Stainforth                         Tel: 020 7838 6700   Daniel Stewart & Company plc Oliver Rigby                                        Tel: 020 7776 6550   This information is provided by RNS The company news service from the London Stock Exchange   END     MSCBUGDXDGGBGGX

TIDMDLTA RNS Number : 0636I Valmont Industries Inc 04 March 2010 ? NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION (INCLUDING CANADA AND JAPAN) OR ANY OTHER JURISDICTION WHERE TO DO THE SAME WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 4 March 2010 Recommended Cash Offer by Valmont Group Pty Ltd, a wholly-owned subsidiary of Valmont Industries, Inc., for Delta plc Summary · The Boards of Valmont Industries, Inc. ("Valmont") and Delta plc ("Delta") are pleased to announce that they have agreed the terms of a recommended cash offer to be made by Valmont Group Pty Ltd (the "Offeror"), a wholly-owned subsidiary of Valmont, to acquire the entire issued and to be issued ordinary share capital of Delta. · The Offer will comprise 185 pence in cash for each Delta Share (the "Offer Price"), valuing the entire existing issued ordinary share capital of Delta at approximately GBP284.5 million. · The Offer Price represents a premium of approximately: · 20.3 per cent. to the closing price of 153.8 pence for each Delta Share on 3 March 2010, the latest practicable Business Day prior to the date of this announcement; · 24.7 per cent. to the average closing price of 148.4 pence for each Delta Share for the month prior to and including 3 March 2010; and · 27.3 per cent. to the average closing price of 145.3 pence for each Delta Share for the three months prior to and including 3 March 2010. · The Offer Price has been determined on the basis that no final dividend in respect of the ordinary share capital of Delta will be paid by Delta in respect of the year ended 31 December 2009. · The Delta Directors, who have been so advised by Rothschild, consider the terms of the Offer to be fair and reasonable and therefore intend unanimously to recommend that Delta Shareholders accept the Offer. In providing such advice, Rothschild has taken into account the commercial assessments of the Delta Directors. · The Offeror has received binding irrevocable undertakings to accept (or procure acceptances of) the Offer from all of the Delta Directors in respect of, in aggregate, 362,627 Delta Shares, representing approximately 0.24 per cent. of the existing issued ordinary share capital of Delta. These undertakings will continue to be binding even in the event of a higher competing offer for Delta being announced, unless the Offer lapses or is withdrawn. · The acquisition of Delta represents an opportunity for Valmont to add additional scale outside the United States in Valmont's core infrastructure markets and to add new growth platforms in strong, fast growing markets. The acquisition of Delta will provide scope for enhanced growth of the Enlarged Group's structures businesses as a result of a greater range of products and a wider geographical presence than the two standalone groups

TIDMISPH RNS Number : 0606I IS Pharma PLC 04 March 2010 ? 4 March 2010 IS Pharma plc ('IS Pharma') IS Pharma acquires exclusive European rights for Episil IS Pharma plc (LSE:ISPH), the international speciality pharmaceutical company, is pleased to announce the acquisition of the exclusive rights for Episil, under a licence and distribution agreement for the major European territories, for a consideration of EUR1.75 million and royalties. Episil is an oncology supportive care product developed by Camurus AB ('Camurus'), a privately owned Swedish life science company. Episil is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment. Episil creates a strongly bioadhesive FluidCrystal film that protects sensitive and sore areas of the mouth. Episil provides prolonged pain reduction for at least eight hours and is presented in a patient friendly multi-dose device. Episil is registered throughout Europe as a Medical Device and is patented to 2025. IS Pharma plans to launch Episil across Europe (excluding the Nordic countries) through 2010 and 2011. The market for such products in Europe is estimated at GBP200 million. IS Pharma has a clear strategy of developing, acquiring and commercialising late-stage pharmaceuticals and medical devices, focused in critical care, oncology and neurology. The acquisition of Episil demonstrates a continuation of delivery against this strategy and the product represents a strong fit with IS Pharma's growing portfolio of oncology products. Episil will create the opportunity for strong sales and distribution synergies with IS Pharma's existing products, Aloxi and Aequasyal. The consideration of EUR1.75 million will be funded through a combination of existing cash resources and a draw down from IS Pharma's debt facilities. As at 30 September 2009 the Group had a cash balance of GBP4.2 million and an undrawn debt facility of GBP4.5 million. Tim Wright, CEO of IS Pharma said: "We are delighted to become Camurus' exclusive partner in Europe for Episil. This partnership represents further success in the delivery of our strategy of building IS Pharma through the acquisition and growth of specialist hospital medicines; with a particular focus on higher margin patented products. "As a patented product, Episil will complement IS Pharma's growing oncology portfolio of products. Distribution through our established European sales and distribution platform will further drive the successful international growth of our business." Fredrik Tiberg, CEO of Camurus said: "We are very pleased to have signed this agreement with IS Pharma who have clearly demonstrated their ability to grow products in the specialist hospital medicines market across Europe. Camurus sees a strong synergy for Episil with IS Pharma's product portfolio and looks forward to the success of the product in Europe." - Ends - +----

LONDON (Dow Jones)--Cash machine company Cashbox PLC (CBOX.LN) Wednesday reported a narrower fiscal first-half loss and said it is confident of meeting full-year market expectations despite the loss of a key client. Cashbox said it will redeploy 300 machines installed at liquor store chain Threshers, which went into administration in November last year. Once redeployed the machines should generate higher income than they did at Threshers, the company said. Cashbox reported a net loss of GBP1.2 million for the six months to Dec. 31, 2009, compared with a loss of GBP1.45 million a year earlier. Revenue advanced 12.8% to GBP3.37 million. Cashbox said it broke even at the earnings before interest, tax, depreciation and amortization level during its fiscal first quarter and is confident it can continue to do so. It didn't provide precise market expectations. Company Web site: www.cashboxplc.co.uk -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com (END) Dow Jones Newswires March 03, 2010 02:45 ET (07:45 GMT)